Quick summary: which helps more with weight loss?
Most evidence shows semaglutide delivers greater average weight loss than liraglutide when paired with diet and activity changes. In a head‑to‑head trial in adults with overweight or obesity, once‑weekly semaglutide 2.4 mg achieved roughly double the average weight loss of once‑daily liraglutide 3 mg at 68 weeks.
- Semaglutide (Wegovy): weekly injection; high average weight loss in trials
- Liraglutide (Saxenda): daily injection; moderate average weight loss
- Side effects: both mainly gastrointestinal and dose‑related
- Access: doctor assessment, prescription and ongoing monitoring required
Key differences at a glance
- Active ingredient and brands
- Liraglutide: Saxenda (weight loss)
- Semaglutide: Wegovy (weight loss), Ozempic (type 2 diabetes), Rybelsus (oral, type 2 diabetes)
- Dosing
- Liraglutide: once daily, titrated to 3.0 mg
- Semaglutide: once weekly for weight loss (Wegovy) titrated to 2.4 mg
- Average trial results
- Semaglutide: often around 15% mean weight loss at ~68 weeks in obesity trials
- Liraglutide: often around 5–8% mean weight loss at ~56–68 weeks
- Side effects: nausea, vomiting, diarrhoea, constipation; typically during dose increases
- Convenience: weekly semaglutide can be easier to adhere to than daily liraglutide for many
Effectiveness evidence: what head‑to‑head and program trials show
Liraglutide and semaglutide are GLP‑1 receptor agonists that reduce appetite, slow gastric emptying and can improve metabolic markers. Weight change varies by person, dose, adherence and support program.
- Head‑to‑head (STEP 8): once‑weekly semaglutide 2.4 mg produced substantially greater mean weight loss than once‑daily liraglutide 3 mg over 68 weeks, with more participants achieving ≥10% and ≥15% loss.
- Semaglutide program trials (STEP series): in people without diabetes using 2.4 mg/week plus lifestyle support, average losses around 15% at 68 weeks were reported.
- Liraglutide program trials (SCALE series): at 3 mg/day plus lifestyle support, average losses commonly in the 5–8% range over ~56 weeks were reported.
Real‑world results depend on careful titration, side‑effect management, nutrition, physical activity and ongoing follow‑up.
Dosing and titration differences
- Liraglutide (Saxenda)
- Daily injection with step‑up titration to 3.0 mg
- Missed doses may affect nausea risk when restarting or increasing
- Semaglutide for weight loss (Wegovy)
- Weekly injection with step‑up titration to 2.4 mg
- Longer half‑life helps with weekly convenience; still requires adherence
Titration aims to balance appetite effects with tolerability. Changes should be guided by your prescriber.
Side effects, safety and warnings
The most common reactions for both are gastrointestinal and typically appear during dose increases or after large meals.
- Common: nausea, vomiting, diarrhoea, constipation, abdominal discomfort, reflux
- Less common but important: gallbladder issues, potential pancreatitis; discuss any severe or persistent abdominal pain promptly
- Warnings: class boxed warning about thyroid C‑cell tumours in rodents; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2
- Use caution with certain medications and conditions; pregnancy and breastfeeding require medical advice
Side‑effect rates and discontinuation can differ across studies; slow and personalised titration often improves tolerability.
Cost and access in Australia
- Prescription and medical supervision are required for both.
- Costs vary by brand, dose, pharmacy and consult fees.
- Ozempic is PBS‑subsidised for type 2 diabetes, not for weight loss. Wegovy and Saxenda are typically private scripts for weight management.
- Availability can be affected by national supply constraints; alternatives or bridging plans may be discussed with your prescriber.
See detailed guides for current pricing and access steps:
Who might suit each option?
- Semaglutide may suit if:
- You prefer weekly injections over daily
- You aim for greater average weight loss based on trial data
- You can access and tolerate gradual dose increases
- Liraglutide may suit if:
- Daily dosing fits your routine and adherence is good
- You’ve had supply issues with semaglutide or prefer its side‑effect profile
- Your clinician recommends it based on your history and medications
The “best” option depends on your medical history, goals, availability, budget and tolerance. A clinician can weigh these factors with you.
Switching between liraglutide and semaglutide
- Common reasons: plateaued results, tolerability, convenience (daily vs weekly), supply
- Typical approach: pause timing, start low on the new medicine, retitrate gradually
- Monitoring: appetite, GI symptoms, hydration, nutrition, activity and relevant labs
Do not stop, start or switch without medical guidance—dose and timing matter for safety and comfort.
Related comparisons and deep dives
Frequently asked questions
Which is better for weight loss: liraglutide or semaglutide?
Semaglutide has shown greater average weight loss than liraglutide in trials, including a direct head‑to‑head study. Individual responses vary—work with a clinician to choose.
How long will I need to stay on treatment?
These medicines are intended for chronic weight management alongside lifestyle changes. Stopping often leads to weight regain. Long‑term plans are discussed with your prescriber.
Are results permanent?
No medicine makes weight loss “permanent.” Sustainable routines plus ongoing medical support improve maintenance after reaching your goal.
Can I take these with other weight loss medicines?
Combining therapies requires medical oversight due to additive side effects and limited evidence for certain pairings. Do not stack without advice.
What if I can’t tolerate the dose increases?
Slower titration, pausing increases, dietary adjustments and timing changes often help. If issues persist, your prescriber may adjust the plan or consider alternatives.
Is oral semaglutide (Rybelsus) used for weight loss?
In Australia, Rybelsus is indicated for type 2 diabetes. Any weight loss use should be discussed with a clinician given indication, dosing and access considerations.
Get personalised guidance
Unsure whether liraglutide or semaglutide suits you? Send a few details and we’ll connect you with an appropriate Australian prescriber or clinic to discuss eligibility, side effects, access and cost.
Prefer to browse first? See our detailed brand guides: Wegovy | Saxenda | Ozempic | Rybelsus
Final takeaway
If your goal is the greatest average weight loss and convenience, semaglutide (weekly) generally outperforms liraglutide (daily) in trials. If access, cost, tolerability or preference favour liraglutide, it remains a valid, evidence‑based option. The right choice is the one you can access, tolerate and sustain—under medical supervision.